Meag Munich Ergo’s BioMarin Pharmaceuticals BMRN Stock Holding History

Meag Munich Ergo’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,018	Closed	-$388K	–	204
2021 Q3	$388K	Hold	5,018	–	–	0.07%	154
2021 Q2	$419K	Sell	5,018 -185	-4%	-$14.7K	0.04%	277
2021 Q1	$393K	Buy	+5,203	New	+$425K	0.04%	275

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Meag Munich Ergo's BMRN Position: Q4 2021 in Review

Meag Munich Ergo sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 5,018 shares — an estimated $388K sold.

Meag Munich Ergo first reported a position in BMRN in Q1 2021 and held it in 3 quarters. The position peaked at $419K in Q2 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Meag Munich Ergo reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Meag Munich Ergo sold 5,018 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $388K.
Meag Munich Ergo first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 3 quarters.
Meag Munich Ergo's BioMarin Pharmaceuticals position peaked at $419K in Q2 2021.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Meag Munich Ergo's 13F filing for Q4 2021, filed 25 Jan 2022.